Rubifen® is indicated as part of a comprehensive treatment program for attention deficit hyperactivity disorder (ADHD) in children from 6 years of age when other measures by themselves have been shown to be insufficient. Treatment should be under the supervision of a specialist in behavioral disorders in children.
Diagnosis should be made according to DMS criteria or ICD-10 guidelines and should be based on a complete history and evaluation of the patient. The diagnosis cannot be made solely on the presence of one or more symptoms.
PVC/Al blister plates. It is marketed:
